Join us for the Davos in the Desert’s 2025 Longevity Sciences Conference, an innovative virtual event that brings together leading executives, pioneering researchers, industry experts, and enthusiasts from around the world.
This conference offers a unique opportunity to delve into the latest advancements in longevity sciences, exploring groundbreaking research and emerging technologies aimed at extending the human health span. Whether you are a scientist, healthcare professional, investor, or simply passionate about longevity, this event is designed to provide valuable insights and foster meaningful connections in the quest to slow down aging and improve quality of life.
Longevity sciences focus on extending the health span by slowing the rate of aging.
The Longevity Sciences Industry is multi-faceted, with new approaches being explored globally. Key segments include:
- Senolytics and Senescence: These focus on removing or rejuvenating senescent cells, which accumulate with age and contribute to various age-related diseases.
- Telomere Research: Telomeres, protective caps at the end of chromosomes, play a role in cellular aging. Research aims to maintain or lengthen telomeres.
- Metabolic Interventions: Caloric restriction, intermittent fasting, and mimetics (such as resveratrol) target metabolic pathways to promote longevity.
- Epigenetics: Understanding how gene expression changes with age and finding ways to modulate it for healthier aging.
- Stem Cell Therapies: Using stem cells to regenerate damaged tissues and organs.
- Biological Clocks: Investigating biological clocks (e.g., circadian rhythms) and their impact on aging.
- NAD+ Boosters: NAD+ is crucial for cellular energy production. Boosting NAD+ levels may enhance health span.
- AI and Longevity: Machine learning and AI help analyze large datasets and identify potential interventions.
It is challenging to determine the exact size of the Longevity Sciences Industry. However, research suggests that the Longevity and Anti-Senescence Therapy Market was valued at roughly $27 billion in 2023 and is predicted to reach nearly $45 billion by 2031, reflecting a 6.8% compound annual growth rate.
In 2022, global longevity investment reached $5.2 billion, with 130 deals. Longevity investment has been on a significant rise over the past decade, from $0.5 billion in 2013 to a peak of $6.2 billion in 2021. Notably, the $3 billion financing for Altos Labs, a company focused on cellular reprogramming, was a landmark deal in 2022.
Each management team will discuss their companies’ scientific approach to enhancing human (or animal) longevity. Topics will include the state of research, research teams, collaborations, and progression through the regulatory process. The presenting executives will also cover addressable markets, payor profiles, pricing strategies, and other go-to-market strategies.